Details of the Drug
General Information of Drug (ID: DMPGM0V)
Drug Name |
1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
BTCP; 112726-66-6; 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine; 1-Btcp; GK 13; 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine; 1-(1-Benzo(b)thien-2-ylcyclohexyl)piperidine; N-(1-(2-Benzo(b)thiophenyl)cyclohexyl)piperidine; GK-13; UNII-Q1WR6UP7MW; Q1WR6UP7MW; CHEMBL279556; CHEBI:64145; 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine; Piperidine, 1-(1-benzo(b)thien-2-ylcyclohexyl)-; 1-(1-benzo[b]thien-2-ylcyclohexyl)Piperidine; Benocyclidine; C19H25NS; Tocris-0702; Lopac-B-138; Biomol-NT_000007; AC1L3X4G; Lopac0_000226
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 299.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 5.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References